The honest answer is narrower than most online content suggests.
A small number of peptides may influence testosterone production indirectly by acting on the body’s own hormonal signaling. Most peptides marketed for testosterone don’t move testosterone levels at all.
Two categories are worth separating before going further:
Most peptides used in men’s health protocols are not FDA-approved for testosterone-related uses, and evidence varies significantly from one compound to another.
Testosterone production runs on a three-stop signaling chain:
The system runs on pulsatile signaling, meaning short bursts at a natural rhythm rather than a constant signal. When that rhythm breaks down upstream, it’s called secondary hypogonadism. When the testes themselves stop responding, it’s primary hypogonadism.
Peptides that act upstream on the HPG axis may stimulate the body’s own testosterone production. Peptides acting on unrelated pathways, such as growth hormone, tissue repair, or central nervous system arousal, won’t directly raise testosterone, even when they help with symptoms commonly associated with low T.
Kisspeptin is a neuropeptide that acts upstream of GnRH, triggering the cascade that ends in testosterone production. In a study published in The Journal of Clinical Endocrinology & Metabolism, intravenous kisspeptin-10 produced rapid LH secretion and corresponding testosterone increases in healthy men. Building on those findings, a 2023 randomized clinical trial in JAMA Network Open found that kisspeptin-54 modulated sexual brain processing and increased penile tumescence in men with hypoactive sexual desire disorder, suggesting effects beyond hormone numbers alone.
The practical catch is short half-life. Kisspeptin-10 clears in about four minutes, which has kept clinical use largely confined to research settings using intravenous infusions. As a result, kisspeptin is not FDA-approved for testosterone support, and despite the promising data, it isn’t a clinic-ready protocol for most men in 2026.
Gonadorelin is a synthetic version of GnRH that directly stimulates the pituitary to release LH and FSH. LH then signals the testes to produce testosterone, and because it mimics the body’s natural pulsatile signal when administered correctly, it works alongside the HPG axis rather than overriding it.
Its regulatory picture has shifted in recent years, and the change matters for how men actually access it today. The FDA-approved brand-name version of gonadorelin, Factrel, was indicated for diagnostic evaluation of the HPG axis and for ovulation induction in women, but that manufactured product has been discontinued in the United States. The compound itself is still legally prescribed through licensed compounding pharmacies, and use in men remains off-label.
That discontinuation, paired with FDA action on compounded human chorionic gonadotropin (hCG), is part of why compounded gonadorelin has become a more commonly prescribed option in men’s health protocols, particularly to help preserve testicular function in men on TRT. Response varies, and it may not fully maintain fertility or intratesticular testosterone in all men, so it should be considered as part of a broader, clinician-guided plan rather than a standalone testosterone booster.
Sermorelin, CJC-1295, and ipamorelin stimulate the pituitary to release growth hormone in natural pulses. Their primary, well-established mechanism is GH release, not testosterone production. That said, some early evidence has suggested possible secondary effects on the HPG axis.
A 2020 review in Translational Andrology and Urology cites a pediatric study in which sermorelin produced small acute rises in FSH and LH alongside GH, and notes that a follow-up animal study reported increased testosterone secretion in GH-deficient rats. Human clinical evidence specifically supporting sermorelin as a testosterone-raising therapy in adult men is limited, and the compound is often marketed for “T support” largely because it may improve sleep depth, recovery, and body composition, which are symptoms commonly confused with low testosterone.
Sermorelin was originally FDA-approved for pediatric growth hormone deficiency, though the manufactured brand-name product was withdrawn from the U.S. market in 2002 and is now accessed through compounding pharmacies. CJC-1295 and ipamorelin are not FDA-approved, and several growth hormone secretagogues are flagged under the FDA’s bulk drug substance framework.
Readers searching for the best peptide to increase testosterone are usually weighing peptides against testosterone replacement therapy. Here is the short comparison:
HPG-Axis Peptides | TRT | |
Mechanism | Signals the body to produce its own testosterone | Replaces testosterone directly |
Effect on natural production | May preserve or stimulate it | Body typically downregulates its own production |
Best fit for | Men with intact HPG axis function; fertility-conscious men | Men with clinically confirmed hypogonadism |
Fertility impact | May preserve fertility | Often suppresses fertility while on therapy |
FDA-approved for testosterone in men? | Generally no (off-label or investigational) | Yes, for specific forms of hypogonadism |
Reversibility | Often easier to cycle off | Long-term commitment in most cases |
TRT is generally the established option when bloodwork confirms hypogonadism. A peptide-based approach may be considered when the goal is preserving the body’s own production, supporting fertility, or addressing symptoms that aren’t purely testosterone-driven. In April 2026, the FDA signaled willingness to evaluate expanded testosterone therapy indications based on emerging clinical evidence.
Work with a licensed clinician, not an online store. Sourcing through licensed pharmacies matters more than ever in 2026 given increased FDA enforcement on compounded and unverified peptide products.
The FDA has issued warning letters to telehealth and compounding operations marketing unverified peptide products, and continues to flag adverse events tied to grey-market sourcing. Several peptides commonly discussed in men’s health, including BPC-157, CJC-1295, and ipamorelin, are named on the FDA’s bulk drug substance list as compounds whose use in compounding may present significant safety risks.
Common side effects of HPG-axis peptides may include injection-site reactions, headache, and transient hormonal fluctuations. Risks rise sharply with unverified sourcing or protocols without baseline labs. Peptide therapy isn’t appropriate for everyone, and any protocol involving the HPG axis requires medical supervision.
There isn't one universal answer. Kisspeptin and gonadorelin are the most mechanistically relevant peptides for testosterone, and both act on the HPG axis to stimulate the body's own signaling rather than replacing testosterone. Each has limitations, and both are typically off-label or investigational for that purpose.
It's a different tool with a different risk profile, not safer or riskier in a blanket sense. Safety depends on the protocol, sourcing, medical supervision, and the underlying condition being treated.
Possibly, depending on the cause of low testosterone. Men with primary (testicular) hypogonadism generally don't respond well to HPG-axis peptides because the issue isn't with upstream signaling.
HPG-axis peptides like gonadorelin may produce hormonal shifts within weeks. Noticeable symptom changes typically follow over several weeks to months.
Most are not approved for testosterone-specific use in men. Gonadorelin is FDA-approved for diagnostic and fertility uses, with off-label men's health applications. Kisspeptin remains investigational.
Costs vary by the peptide, protocol, and provider model.
The honest answer to what peptides increase testosterone is narrower than most online content suggests. A handful may meaningfully influence testosterone through the HPG axis, several more may help with testosterone-related symptoms without raising the hormone itself, and many marketed as “T-boosting” don’t belong in the conversation at all.
The right approach depends on your labs, your goals, and the medical supervision behind the protocol. Peptide therapy isn’t appropriate for everyone, and the safest path runs through a licensed clinician who can match the tool to your situation.
If you’re considering peptide therapy and want a physician-guided approach grounded in labs and realistic expectations, Beyond Biology can help you evaluate your options and design a plan around your health profile.
This blog is for informational and educational purposes only and should not be considered medical advice, diagnosis, or treatment. Peptide therapy may not be appropriate for everyone, and costs, availability, insurance coverage, and treatment options can vary based on individual health needs, provider guidance, and applicable regulations. Always consult a qualified healthcare professional before starting any peptide therapy or wellness protocol.